From: Loss of ZG16 is associated with molecular and clinicopathological phenotypes of colorectal cancer
Clinical-pathological features | Number of cases | Gene expression (average) | P | |
---|---|---|---|---|
Gender | ||||
male | 94 | 0.512 | 0.037 | |
female | 99 | − 0.487 | ||
Colon polyps present | ||||
yes | 73 | −0.768 | 0.246 | |
no | 129 | −1.109 | ||
Anatomic neoplasm subdivision | ||||
ascending colon | 86 | 0.499 | 0.020 | |
descending colon | 20 | 1.681 | ||
Histological type | ||||
adenocarcinoma | 62 | −0.98 | 0.244 | |
mucinous- adenocarcinoma | 385 | −0.41 | ||
Lymphatic invasion | ||||
yes | 77 | −1.136 | 0.793 | |
no | 175 | −1.032 | ||
Pathological-N | N2 N0 | 48,167 | − 1.464 -0.806 | 0.0072 |
Hyper-mutation status | ||||
true | 32 | −1.23 | 0.018 | |
false | 119 | 0.571 | ||
Microsatellite instability status | ||||
MSI-H | 25 | −1.58 | 0.037 | |
MSI-L | 25 | 1.13 | ||
MSS | 98 | 0.491 | ||
MLH1 silencing | ||||
yes | 20 | −1.143 | 0.043 | |
no | 120 | 0.563 | ||
CpG island methylator phenotype | ||||
CIMP-H | 29 | −0.74 | 0.38 | |
CIMP-L | 35 | −0.24 | ||
Treatment success status | ||||
complete remission | 92 | −0.49 | 0.080 | |
progressive | 28 | −1.91 | ||
Sample type | ||||
primary tumor | 286 | −1.61 | 0.000 | |
tissue normal | 46 | 14.59 |